This startup develops a droplet digital PCR assay for accurate and sensitive detection of gene fusions in blood cancer. This assay enables healthcare providers to monitor disease progression and assess treatment response with rapid turnaround and reduced costs.
Funding
Funding not disclosed
Founders
Product
Problem
Monitoring minimal residual disease (MRD) in blood cancers often relies on methods like flow cytometry or sequencing, which can lack the sensitivity to detect low levels of fusion transcripts, potentially delaying intervention. Traditional methods can also be expensive and time-consuming, hindering frequent monitoring and timely treatment adjustments.
Solution
Pairidex offers a droplet digital PCR (ddPCR) assay service for highly sensitive and accurate detection of gene fusions in blood cancers, enabling personalized MRD monitoring. Their CLIA-certified lab provides rapid turnaround times and cost-effective testing, allowing for more frequent monitoring of disease progression and treatment response. The assay achieves exceptional sensitivity, detecting as little as one fusion transcript in 100,000 cells, while maintaining a low false-positive rate. By targeting each patient's unique disease-defining gene fusion, the assay ensures accurate and personalized monitoring of their specific cancer.
Target Audience
The primary target audience includes hematologists, oncologists, and researchers involved in blood cancer treatment and monitoring, as well as pharmaceutical companies developing therapies for fusion-driven hematological malignancies.
Features
- Droplet digital PCR (ddPCR) technology for absolute quantification of oncogenic fusion transcripts
- Personalized MRD testing targeting unique disease-defining gene fusions
- High sensitivity, detecting one fusion-bearing cell in 100,000
- Streamlined sample processing and rapid analysis for fast turnaround times
- Cost-effective alternative to sequencing and flow cytometry
- CLIA-certified laboratory testing service
- Tumor-informed assay design